SCHEMBL680999

SCHEMBL680999

Cn1ncc2cc(Oc3ccc(N)cc3F)c(-c3cnn(C(=O)O)c3)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 1/20 0.42
NTRK1 P04629 1/20 0.42
RET P07949 1/20 0.42
MET P08581 1/20 0.42
AXL P30530 1/20 0.42
KDR P35968 1/20 0.42
FLT3 P36888 1/20 0.42
MST1R Q04912 1/20 0.42
DDR1 Q08345 1/20 0.42
MERTK Q12866 1/20 0.42
CAMK4 Q16566 1/20 0.42
DDR2 Q16832 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
CACNA1H O95180 10/20 0.38
AR P10275 3/20 0.36
STIM1 Q13586 1/20 0.35
ORAI1 Q96D31 1/20 0.35
MAPK14 Q16539 2/20 0.34
CHEK1 O14757 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680838 0.88 SCN9A (0.45) PLK4NTRK1RETMETAXL
SCHEMBL23081429 0.86 AXL (0.41) PLK4NTRK1RETMETAXL
SCHEMBL680514 0.85 PLK4 (0.41) PLK4NTRK1RETMETAXL
SCHEMBL23629422 0.81 SCN9A (0.43) PLK4NTRK1RETMETAXL
SCHEMBL680022 0.81 CYP11B1 (0.43) PLK4NTRK1RETMETAXL
SCHEMBL680039 0.79 PLK4 (0.55) PLK4NTRK1RETMETAXL
SCHEMBL680681 0.78 CACNA1H (0.42) PLK4NTRK1RETMETAXL
SCHEMBL680695 0.78 AXL (0.41) PLK4NTRK1RETMETAXL
SCHEMBL681000 0.76 AXL (0.78) PLK4NTRK1RETMETAXL
SCHEMBL680415 0.76 ATM (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC PLK4 2609/4885NTRK1 585/4885RET 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.